Osteopontin knockdown suppresses the growth and angiogenesis of colon cancer cells

World Journal of Gastroenterology

Volumn 20, Issue 30, 2014, Pages 10440-10448

  Wu, Xin Lin ^a   Lin, Kai Jin ^b   Bai, Ai Ping ^c   Wang, Wan Xiang ^a   Meng, Xing Kai ^a   Su, Xiu Lan ^a   Hou, Ming Xing ^a   Dong, Pei De ^a   Zhang, Jun Jing ^a   Wang, Zhao Yang ^a   Shi, Lin ^a  

^a The Affiliated Hospital of Inner Mongolia Medical University   (China)

^b Fu Qing City Hospital   (China)

^c NANCHANG UNIVERSITY   (China)

Author keywords

Angiogenesis; Colon carcinoma; Lovo cells; Osteopontin; RNA interference

Indexed keywords

ANTIBIOTIC G 418; GELATINASE A; GELATINASE B; MESSENGER RNA; OSTEOPONTIN; RESTRICTION ENDONUCLEASE; SMALL INTERFERING RNA; UROKINASE; VASCULOTROPIN; MMP2 PROTEIN, HUMAN; MMP9 PROTEIN, HUMAN; SPP1 PROTEIN, HUMAN; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

ABSORPTION; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL LINE; CANCER INHIBITION; CELL ADHESION; CELL ADHESION ASSAY; CELL INVASION; CELL INVASION ASSAY; CELL PROLIFERATION; CELL SELECTION; COLON CANCER; CONTROLLED STUDY; CULTURE MEDIUM; DNA SEQUENCE; ENZYME DEGRADATION; ENZYME LINKED IMMUNOSORBENT ASSAY; EXPRESSION VECTOR; GENE CONSTRUCT; GENE EXPRESSION; GENE INSERTION; GENE SEQUENCE; GENE SILENCING; GENE TARGETING; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IN VITRO STUDY; LIPOSOMAL GENE DELIVERY SYSTEM; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; RECOMBINANT PLASMID; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA SEQUENCE; RNA SYNTHESIS; TUMOR INVASION; WESTERN BLOTTING; COLONIC NEOPLASMS; DOWN REGULATION; GENE EXPRESSION REGULATION; GENE THERAPY; GENETICS; METABOLISM; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; PROCEDURES; RNA INTERFERENCE; TUMOR CELL LINE;

CELL ADHESION; CELL LINE, TUMOR; CELL PROLIFERATION; COLONIC NEOPLASMS; DOWN-REGULATION; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE KNOCKDOWN TECHNIQUES; GENETIC THERAPY; HUMANS; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; NEOPLASM INVASIVENESS; NEOVASCULARIZATION, PATHOLOGIC; OSTEOPONTIN; RNA INTERFERENCE; RNA, MESSENGER; TRANSFECTION; UROKINASE-TYPE PLASMINOGEN ACTIVATOR; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84911360958     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v20.i30.10440     Document Type: Article

References (36)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011; 61: 69-90 [PMID: 21296855 DOI: 10.3322/caac.20107]
2. Chiodoni C, Colombo MP, Sangaletti S. Matricellular proteins: from homeostasis to inflammation, cancer, and metastasis. Cancer Metastasis Rev 2010; 29: 295-307 [PMID: 20386958 DOI: 10.1007/s10555-010-9221-8]
3. Standal T, Borset M, Sundan A. Role of osteopontin in adhesion, migration, cell survival and bone remodeling. Exp Oncol 2004; 26: 179-184 [PMID: 15494684]
4. Hopps L. Road to confidence. Nurs Times 1988; 84: 38-39 [PMID: 3419986 DOI: 10.3748/wjg.v18.i30.3923]
5. Huang J, Pan C, Hu H, Zheng S, Ding L. Osteopontinenhanced hepatic metastasis of colorectal cancer cells. PLoS One 2012; 7: e47901 [PMID: 23112867 DOI: 10.1371/journal. pone.0047901]
6. Phillips RJ, Helbig KJ, Van der Hoek KH, Seth D, Beard MR. Osteopontin increases hepatocellular carcinoma cell growth in a CD44 dependant manner. World J Gastroenterol 2012; 18: 3389-3399 [PMID: 22807608 DOI: 10.3748/wjg.v18. i26.3389]
7. Sun L, Pan J, Peng L, Fang L, Zhao X, Sun L, Yang Z, Ran Y. Combination of haptoglobin and osteopontin could predict colorectal cancer hepatic metastasis. Ann Surg Oncol 2012; 19: 2411-2419 [PMID: 22219064 DOI: 10.1245/s10434-011-2177-2]
8. Macrì A, Versaci A, Lupo G, Trimarchi G, Tomasello C, Loddo S, Sfuncia G, Caminiti R, Teti D, Famulari C. Role of osteopontin in breast cancer patients. Tumori 2009; 95: 48-52 [PMID: 19366056]
9. Zhang X, Tsukamoto T, Mizoshita T, Ban H, Suzuki H, Toyoda T, Tatematsu M. Expression of osteopontin and CDX2: indications of phenotypes and prognosis in advanced gastric cancer. Oncol Rep 2009; 21: 609-613 [PMID: 19212618 DOI: 10.3892/or-00000263]
10. Boldrini L, Donati V, Dell'Omodarme M, Prati MC, Faviana P, Camacci T, Lucchi M, Mussi A, Santoro M, Basolo F, Fontanini G. Prognostic significance of osteopontin expression in early-stage non-small-cell lung cancer. Br J Cancer 2005; 93: 453-457 [PMID: 16091764]
11. Hass HG, Nehls O, Jobst J, Frilling A, Vogel U, Kaiser S. Identification of osteopontin as the most consistently overexpressed gene in intrahepatic cholangiocarcinoma: detection by oligonucleotide microarray and real-time PCR analysis. World J Gastroenterol 2008; 14: 2501-2510 [PMID: 18442196 DOI: 10.3748/wjg.14.2501]
12. Likui W, Hong W, Shuwen Z, Yuangang Y, Yan W. The potential of osteopontin as a therapeutic target for human colorectal cancer. J Gastrointest Surg 2011; 15: 652-659 [PMID: 21318445 DOI: 10.1007/s11605-011-1445-6]
13. Tang H, Wang J, Bai F, Hong L, Liang J, Gao J, Zhai H, Lan M, Zhang F, Wu K, Fan D. Inhibition of osteopontin would suppress angiogenesis in gastric cancer. Biochem Cell Biol 2007; 85: 103-110 [PMID: 17464350 DOI: 10.1016/0092-8674( 79)90103-X]
14. Oldberg A, Franzén A, Heinegard D. Cloning and sequence analysis of rat bone sialoprotein (osteopontin) cDNA reveals an Arg-Gly-Asp cell-binding sequence. Proc Natl Acad Sci USA 1986; 83: 8819-8823 [PMID: 3024151 DOI: 10.1073/pnas.83.23.8819]
15. Wai PY, Kuo PC. Osteopontin: regulation in tumor metastasis. Cancer Metastasis Rev 2008; 27: 103-118 [PMID: 18049863 DOI: 10.1007/s10555-007-9104-9]
16. Likui W, Hong W, Shuwen Z. Clinical significance of the upregulated osteopontin mRNA expression in human colorectal cancer. J Gastrointest Surg 2010; 14: 74-81 [PMID: 19763701 DOI: 10.1007/s11605-009-1035-z]
17. Irby RB, McCarthy SM, Yeatman TJ. Osteopontin regulates multiple functions contributing to human colon cancer development and progression. Clin Exp Metastasis 2004; 21: 515-523 [DOI: 10.1007/s10585-004-2873-4]
18. Shi L, Han F, Zhang JT, Wu XL. The experimental study of the relationship of osteopontin and biological characteristics of oral carcinoma cell lines. Kouqing Yixue 2012; 32: 333-335, 346
19. Liotta LA, Mandler R, Murano G, Katz DA, Gordon RK, Chiang PK, Schiffmann E. Tumor cell autocrine motility factor. Proc Natl Acad Sci USA 1986; 83: 3302-3306 [PMID: 3085086 DOI: 10.1073/pnas.83.10.3302]
20. Ishihara Y, Nishikawa T, Iijima H, Matsunaga K. Expression of matrix metalloproteinase, tissue inhibitors of metalloproteinase and adhesion molecules in silicotic mice with lung tumor metastasis. Toxicol Lett 2003; 142: 71-75 [PMID: 12765241 DOI: 10.1016/s0378-4274(02)00486-1]
21. Du XL, Jiang T, Sheng XG, Gao R, Li QS. Inhibition of osteopontin suppresses in vitro and in vivo angiogenesis in endometrial cancer. Gynecol Oncol 2009; 115: 371-376 [PMID: 19783287 DOI: 10.1016/j.ygyno.2009.08.029]
22. Hamada Y, Nokihara K, Okazaki M, Fujitani W, Matsumoto T, Matsuo M, Umakoshi Y, Takahashi J, Matsuura N. Angiogenic activity of osteopontin-derived peptide SVVYGLR. Biochem Biophys Res Commun 2003; 310: 153-157 [PMID: 14511663 DOI: 10.1016/j.bbrc.2003.09.001]
23. Dai J, Peng L, Fan K, Wang H, Wei R, Ji G, Cai J, Lu B, Li B, Zhang D, Kang Y, Tan M, Qian W, Guo Y. Osteopontin induces angiogenesis through activation of PI3K/AKT and ERK1/2 in endothelial cells. Oncogene 2009; 28: 3412-3422 [PMID: 19597469 DOI: 10.1038/onc.2009.189]
24. Chen RX, Xia YH, Xue TC, Zhang H, Ye SL. Down-regulation of osteopontin inhibits metastasis of hepatocellular carcinoma cells via a mechanism involving MMP-2 and uPA. Oncol Rep 2011; 25: 803-808 [PMID: 21174062 DOI: 10.3892/or.2010.1116]
25. Chen YJ, Wei YY, Chen HT, Fong YC, Hsu CJ, Tsai CH, Hsu HC, Liu SH, Tang CH. Osteopontin increases migration and MMP-9 up-regulation via alphavbeta3 integrin, FAK, ERK, and NF-kappaB-dependent pathway in human chondrosarcoma cells. J Cell Physiol 2009; 221: 98-108 [PMID: 19475568]
26. Liu H, Chen A, Guo F, Yuan L. A short-hairpin RNA targeting osteopontin downregulates MMP-2 and MMP-9 expressions in prostate cancer PC-3 cells. Cancer Lett 2010; 295: 27-37 [PMID: 20207476 DOI: 10.1016/j.canlet.2010.02.012]
27. Agrawal D, Chen T, Irby R, Quackenbush J, Chambers AF, Szabo M, Cantor A, Coppola D, Yeatman TJ. Osteopontin identified as colon cancer tumor progression marker. C R Biol 2003; 326: 1041-1043 [PMID: 14744111 DOI: 10.1016/j.crvi.2003.09.007]
28. Robertson BW, Chellaiah MA. Osteopontin induces betacatenin signaling through activation of Akt in prostate cancer cells. Exp Cell Res 2010; 316: 1-11 [PMID: 19850036 DOI: 10.1016/j.yexcr.2009.10.012]
29. Smit DJ, Gardiner BB, Sturm RA. Osteonectin downregulates E-cadherin, induces osteopontin and focal adhesion kinase activity stimulating an invasive melanoma phenotype. Int J Cancer 2007; 121: 2653-2660 [PMID: 17724718 DOI: 10.1002/ijc.23039]
30. Chakraborty G, Jain S, Kale S, Raja R, Kumar S, Mishra R, Kundu GC. Curcumin suppresses breast tumor angiogenesis by abrogating osteopontin-induced VEGF expression. Mol Med Rep 2008; 1: 641-646 [PMID: 21479462 DOI: 10.3892/mmr-00000005]
31. Rangaswami H, Kundu GC. Osteopontin stimulates melanoma growth and lung metastasis through NIK/MEKK1- dependent MMP-9 activation pathways. Oncol Rep 2007; 18: 909-915 [PMID: 17786354]
32. Waas ET, Wobbes T, Lomme RM, DeGroot J, Ruers T, Hendriks T. Matrix metalloproteinase 2 and 9 activity in patients with colorectal cancer liver metastasis. Br J Surg 2003; 90: 1556-1564 [PMID: 14648736 DOI: 10.1002/bjs.4346]
33. Li XD, Chen J, Ruan CC, Zhu DL, Gao PJ. Vascular endothelial growth factor-induced osteopontin expression mediates vascular inflammation and neointima formation via Flt-1 in adventitial fibroblasts. Arterioscler Thromb Vasc Biol 2012; 32: 2250-2258 [PMID: 22814749 DOI: 10.1161/ATVBAHA. 112.255216]
34. Kaneko T, Konno H, Baba M, Tanaka T, Nakamura S. Urokinase-type plasminogen activator expression correlates with tumor angiogenesis and poor outcome in gastric cancer. Cancer Sci 2003; 94: 43-49 [PMID: 12708473 DOI: 10.1111/j.1349-7006.2003.tb01350.x]
35. Chen RX, Xia YH, Xue TC, Ye SL. Osteopontin promotes hepatocellular carcinoma invasion by up-regulating MMP-2 and uPA expression. Mol Biol Rep 2011; 38: 3671-3677 [PMID: 21104439 DOI: 10.1007/s11033-010-0481-8]
36. Tilli TM, Mello KD, Ferreira LB, Matos AR, Accioly MT, Faria PA, Bellahcène A, Castronovo V, Gimba ER. Both osteopontin- c and osteopontin-b splicing isoforms exert protumorigenic roles in prostate cancer cells. Prostate 2012; 72: 1688-1699 [PMID: 22495819 DOI: 10.1002/pros.22523]